I agree with Dr Michalak and Dr Lam on 2 points. First, I agree that light therapy works-but it is similarly helpful in nonseasonal mood disorders (7) , and some medications, such as tranylcypromin, work even better in reputed cases of SAD. Second, I agree that a large number of articles have indeed been published about SAD-but frequent repetition alone does not make the disorder real. In fact, that's how myths have often been created in psychiatry: consider, for example, the extensive earlier literature on entities such as "involutional melancholia" and "anniversary depression" (the psychoanalytic precursor of SAD). Without evidence, such entities sooner or later become history.
I have collected lifetime data on the clinical course of nearly 2000 patients with mood disorders, and I have approached 2 colleagues who claim to specialize in SAD, yet I still have not come across a single patient with several recurrences limited mostly to a particular season. If Dr Michalak and Dr Lam have at least a couple of patients who actually continue meeting the criteria for SAD for an extended period, I would be happy to interview the patients and publicly recant my solid skepticism about SAD. 
Seasonal Affective Disorder: The Latitude Hypothesis Revisited
Dear Editor:
Axelsson and others' recent article concerning the prevalence of seasonal affective disorder (SAD) in people of Icelandic decent makes for interesting reading (1) . The authors report that people of wholly Icelandic descent living in Winnipeg, Manitoba, show significantly lower rates of seasonality than do residents of non-Icelandic decent (as measured by the Seasonal Pattern Assessment Questionnaire [SPAQ] [2] ). This finding complements those of an earlier study conducted in the Interlake District of Manitoba (3). The authors conclude that genetic factors play an important role in the etiology of SAD, and they express some doubt regarding the veracity of the "latitude hypothesis," which posits a higher prevalence of SAD in more northern latitudes, owing to the shorter winter day.
An earlier review of epidemiological studies in this area did not find a significant overall correlation between prevalence of SAD and latitude (r [n = 13] = 0.07, P = 0.42) (4). However, the authors did observe meaningful correlations between SAD and latitude when the studies were split into those conducted in North America (r [n = 7] = 0.90, P = 0.003) and those conducted in Europe (r [n = 6] = 0.70, P = 0.06). While this review provided a useful contribution, it had some limitations: it included several studies not published in peer-reviewed journals, and it omitted published work conducted in areas outside North America and Europe.
To further inform this issue, we performed a slightly different quantitative synthesis of the literature. We included all peer-reviewed studies published before October 2000 that examined the prevalence of SAD using the SPAQ (n = 22), irrespective of the country in which they were conducted. We analyzed the studies in 2 separate categories: those conducted in general population samples (which are more representative of overall prevalence at any given latitude) and those performed in specific subpopulations. Where studies had been performed over several latitudes, we calculated mean prevalence rates and latitudes.
The results of this analysis showed a significant correlation between SAD and latitude in the general population studies (r [n = 12] = 0.66, P = 0.019) and an insignificant correlation in the specific subgroup studies (r [n = 10] = 0.34, P = 0.34).
Our results suggest that the prevalence of SAD in the general population does increase with higher latitude, consistent with the latitude hypothesis. However, although latitude does reflect the daily photoperiod in a given location, it is likely to be only a crude measure of other variables, such as climatic conditions. These studies are also limited by the fact that the SPAQ does not provide clinical diagnoses. We agree with Axelsson and others' view (1) that SAD probably has a complex etiology and pathophysiology (5) influenced by several variables, such as environment, genetics, sociocultural context, and psychosocial factors. Nevertheless, given the study results, we do not wish to potentially "throw the baby out with the bathwater" and discontinue studying the relation between SAD and latitude. 
Treatment Of Posttraumatic Stress Disorder With Tiagabine
Posttraumatic stress disorder (PTSD) can be a debilitating condition with impairment as bad as, or worse than, that caused by other psychiatric illnesses (1). Symptomatology includes a triad of symptoms from 3 clusters: persistent reexperiencing of the trauma (for example, intrusive and distressing recollections, nightmares, and dissociative flashbacks); persistent avoidance of stimuli associated with the trauma; and persistent symptoms of increased autonomic arousal (2) . Because the symptoms of PTSD can vary across the symptom clusters, medications from different classes are needed to treat patients. Based on the hypothesis that kindling of the limbic nuclei occurs following the trauma (3-5), anticonvulsants such as carbamezapine and valproate were used to treat PTSD as far back as the mid-1980s to the early 1990s, (6, 7) . Newer anticonvulsants such as lamotrigene, gabapentin, and topiramate have also been used (8) (9) (10) .
I present the case of a patient diagnosed with PTSD and major depressive disorder (MDD) who had taken multiple medications in the past and received benefit from tiagabine. To date, there are no reports in the literature describing the use of tiagabine to treat PTSD.
Case Report
Mr A is a 43-year-old man with a history of PTSD and MDD. His illness caused significant impairment over the years, and he had been treated with the following agents: sertraline, paroxetine, fluoxetine, buproprion augmented with lithium, trazadone, nefazodone, gabapentin, and topiramate.
Upon consultation, Mr A agreed to a trial of venlafaxine extended release (XR), started at 37.5 mg daily and titrated to 225 mg daily over 3 weeks. After 1 month, he noted an improvement in his depressive symptoms, but he was still experiencing intrusive thoughts, nightmares, and hypervigilance. He agreed to a trial of tiagabine, initiated at 2 mg daily. His dosage was increased by weekly 2 mg increments to 8 mg daily, at which level he began to notice an improvement in his intrusive thoughts and nightmares-even through the traumatic events of September 11, 2001 , which provided a flood of external cues. He occasionally takes zolpidem tartrate 10 mg for insomnia, but over the past 6 months he has improved significantly, to the point of returning to work full-time. He cannot recall feeling this stable during the last 10 years.
Tiagabine is FDA-approved as an adjunct anticonvulsant for the treatment of partial seizures (11) . It is thought to exert its action by inhibiting GABA from the synaptic cleft (12, 13) . Tiagabine has also been shown to have antikindling potency (14) , making it a potential candidate in treating PTSD. This patient's improvement might have been due to a combination of agents, but the addition of tiagabine clearly led to a reduction in the reexperiencing symptoms. Further controlled studies are needed to investigate the efficacy of tiagabine in treating PTSD.
